Zymergen was a synthetic biology company that combined machine learning, automation, and genetic engineering to develop microorganisms for manufacturing materials and chemicals. The company aimed to replace traditional chemical processes with biological alternatives for industries like electronics, agriculture, and consumer goods. Despite going public in 2021, Zymergen struggled commercially and was acquired by Ginkgo Bioworks in 2022 for $300M, significantly below its previous valuation.
Zymergen has received investment from 3 venture capital firms.
Biomanufacturing company using machine learning and automation to engineer microbes for producing materials.
Zymergen has received investment from IndieBio, Innovation Endeavors, Refactor Capital. These venture capital firms and investors provide both capital and strategic support.
Zymergen has raised $874M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Zymergen was founded in 2013 and is headquartered in Emeryville, California.
Zymergen operates in the Biotech sector. Biomanufacturing company using machine learning and automation to engineer microbes for producing materials.
